CoChat
Sign Up
Cited by 260Muscle Physiology and DisordersNutrition and Health in AgingMuscle metabolism and nutrition

The DOI matches its Crossref record; 78 of the 82 references it cites were found in a registry or an index.

The Regulation of Skeletal Muscle Protein Turnover during the Progression of Cancer Cachexia in the ApcMin/+ Mouse

Open access
White, James P., Baynes, John W., Welle, Stephen L., Kostek, Matthew C., Matesic, Lydia E., Sato, Shuichi, Carson, James A.·2011·PLoS ONE
DOI 10.1371/journal.pone.0024650PMC PMC3176277
Open this paper in CoChat — free accountOpen PDF

Abstract

Muscle wasting that occurs with cancer cachexia is caused by an imbalance in the rates of muscle protein synthesis and degradation. The Apc(Min/+) mouse is a model of colorectal cancer that develops cachexia that is dependent on circulating IL-6. However, the IL-6 regulation of muscle protein turnover during the initiation and progression of cachexia in the Apc(Min/+) mouse is not known. Cachexia progression was studied in Apc(Min/+) mice that were either weight stable (WS) or had initial (≤5%), intermediate (6-19%), or extreme (≥20%) body weight loss. The initiation of cachexia reduced %MPS 19% and a further ∼50% with additional weight loss. Muscle IGF-1 mRNA expression and mTOR targets were suppressed with the progression of body weight loss, while muscle AMPK phosphorylation (Thr 172), AMPK activity, and raptor phosphorylation (Ser 792) were not increased with the initiation of weight loss, but were induced as cachexia progressed. ATP dependent protein degradation increased during the initiation and progression of cachexia. However, ATP independent protein degradation was not increased until cachexia had progressed beyond the initial phase. IL-6 receptor antibody administration prevented body weight loss and suppressed muscle protein degradation, without any effect on muscle %MPS or IGF-1 associated signaling. In summary, the %MPS reduction during the initiation of cachexia is associated with IGF-1/mTOR signaling repression, while muscle AMPK activation and activation of ATP independent protein degradation occur later in the progression of cachexia. IL-6 receptor antibody treatment blocked cachexia progression through the suppression of muscle protein degradation, while not rescuing the suppression of muscle protein synthesis. Attenuation of IL-6 signaling was effective in blocking the progression of cachexia, but not sufficient to reverse the process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0024650

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Muscle protein synthesis and IGF-1/mTOR signaling are reduced during the progression of cachexia in ApcMin/+ mice. Protein synthesis and IGF-1 expression were measured in ApcMin/+ mice during the progression of cachexia. A) Myofibrillar protein synthesis. B) Correlation between muscle weights and protein synthesis. C) Upper: representative western blot of phosphorylated and total forms of Akt (Ser 473), mTOR (Ser2448), p70S6k (Thr389) and 4EBP-1 (Thr37/46). Lower: The ratio of phosphorylated and total Akt, mTOR, p70 and 4EBP1 in the gastrocnemius muscle normalized to the WS group. D) IGF-1 expression and E) correlation between IGF-1 gene expression and protein synthesis. F) Skeletal alpha actin mRNA expression. Values are means ± SE. Significance was set at p<0.05. † Signifies different from WS mice. & Signifies difference from mice with ≤5% body weight loss. $ Signifies difference from mice with 6–19% body weight loss. WS, weight stable.
Figure 1 Muscle protein synthesis and IGF-1/mTOR signaling are reduced during the progression of cachexia in ApcMin/+ mice. Protein synthesis and IGF-1 expression were measured in ApcMin/+ mice during the progression of cachexia. A) Myofibrillar protein synthesis. B) Correlation between muscle weights and protein synthesis. C) Upper: representative western blot of phosphorylated and total forms of Akt (Ser 473), mTOR (Ser2448), p70S6k (Thr389) and 4EBP-1 (Thr37/46). Lower: The ratio of phosphorylated and total Akt, mTOR, p70 and 4EBP1 in the gastrocnemius muscle normalized to the WS group. D) IGF-1 expression and E) correlation between IGF-1 gene expression and protein synthesis. F) Skeletal alpha actin mRNA expression. Values are means ± SE. Significance was set at p<0.05. † Signifies different from WS mice. & Signifies difference from mice with ≤5% body weight loss. $ Signifies difference from mice with 6–19% body weight loss. WS, weight stable.CC BY · PubMed Central
Figure 2 AMPK activation increases during late stage cachexia. AMPK activation was measured in ApcMin/+ mice during the progression of cachexia. A) AMPK activity in the gastrocnemius muscle normalized to the WS mice. B) Upper: representative western blot of phosphorylated AMPK (Thr172) and total AMPK in the gastrocnemius. Lower: The ratio of phosphorylated to total forms of AMPK in the gastrocnemius muscle. C) Upper: representative western blot of phosphorylated raptor (Ser792) and total raptor in the gastrocnemius. Lower: The ratio of phosphorylated to total forms of raptor in the gastrocnemius muscle. Values are means ± SE. Significance was set at p<0.05. † Signifies different from WS mice. & Signifies difference from mice with ≤5% body weight loss. $ Signifies difference from mice with 6–19% body weight loss. WS, weight stable.
Figure 2 AMPK activation increases during late stage cachexia. AMPK activation was measured in ApcMin/+ mice during the progression of cachexia. A) AMPK activity in the gastrocnemius muscle normalized to the WS mice. B) Upper: representative western blot of phosphorylated AMPK (Thr172) and total AMPK in the gastrocnemius. Lower: The ratio of phosphorylated to total forms of AMPK in the gastrocnemius muscle. C) Upper: representative western blot of phosphorylated raptor (Ser792) and total raptor in the gastrocnemius. Lower: The ratio of phosphorylated to total forms of raptor in the gastrocnemius muscle. Values are means ± SE. Significance was set at p<0.05. † Signifies different from WS mice. & Signifies difference from mice with ≤5% body weight loss. $ Signifies difference from mice with 6–19% body weight loss. WS, weight stable.CC BY · PubMed Central
Figure 3 Skeletal muscle protein degradation consists of ATP dependent and independent mechanisms during the progression of cachexia in the ApcMin/ mice. Protein degradation was measured in ApcMin/+ mice with progressive body weight loss. A) Protein degradation determined by tyrosine release assay. White bars represent ATP dependent degradation; Black bars represent ATP independent degradation. B) Correlation between protein degradation and gastrocnemius weight. C) Correlation between protein degradation and the percentage of body weight loss. D) Upper representative western blot of ubiquitinated proteins in the gastrocnemius muscle. Lower Quantification of ubiquitinated proteins normalized to weight stable ApcMin/+ mice. E) Gene expression of C7 and C2 proteasomal subunits. F). Upper: representative western blot of phosphorylated and total forms of Foxo3. Lower: The ratio of phosphorylated and total Foxo3. G) Gene expression of atrogin1 and MuRF1. H) Representative western blot of atrogin1 protein. Values are means ± SE. Significance was set at p<0.05. † Signifies different from WS groups. & Signifies difference from mice with ≤5% body weight loss. WS, weight stable.
Figure 3 Skeletal muscle protein degradation consists of ATP dependent and independent mechanisms during the progression of cachexia in the ApcMin/ mice. Protein degradation was measured in ApcMin/+ mice with progressive body weight loss. A) Protein degradation determined by tyrosine release assay. White bars represent ATP dependent degradation; Black bars represent ATP independent degradation. B) Correlation between protein degradation and gastrocnemius weight. C) Correlation between protein degradation and the percentage of body weight loss. D) Upper representative western blot of ubiquitinated proteins in the gastrocnemius muscle. Lower Quantification of ubiquitinated proteins normalized to weight stable ApcMin/+ mice. E) Gene expression of C7 and C2 proteasomal subunits. F). Upper: representative western blot of phosphorylated and total forms of Foxo3. Lower: The ratio of phosphorylated and total Foxo3. G) Gene expression of atrogin1 and MuRF1. H) Representative western blot of atrogin1 protein. Values are means ± SE. Significance was set at p<0.05. † Signifies different from WS groups. & Signifies difference from mice with ≤5% body weight loss. WS, weight stable.CC BY · PubMed Central
Figure 4 Autophagy is increased during late stage cachexia in the ApcMin/+ mouse. A) Upper representative western blot of Beclin-1 protein. Lower Quantification of Beclin-1 protein normalized to weight stable ApcMin/+ mice, B) Upper representative western blot of Atg7 protein. Lower Quantification of Atg7 protein. C) Upper representative western blot of LC3β protein. Lower Quantification of LC3β protein. Values are means ± SE. Significance was set at p<0.05. † Signifies difference from weight stable ApcMin/+ mice. $ Signifies different from ApcMin/+ mice with 6–19% body weight loss. WS, weight stable.
Figure 4 Autophagy is increased during late stage cachexia in the ApcMin/+ mouse. A) Upper representative western blot of Beclin-1 protein. Lower Quantification of Beclin-1 protein normalized to weight stable ApcMin/+ mice, B) Upper representative western blot of Atg7 protein. Lower Quantification of Atg7 protein. C) Upper representative western blot of LC3β protein. Lower Quantification of LC3β protein. Values are means ± SE. Significance was set at p<0.05. † Signifies difference from weight stable ApcMin/+ mice. $ Signifies different from ApcMin/+ mice with 6–19% body weight loss. WS, weight stable.CC BY · PubMed Central
Figure 5 Inhibition of IL-6 signaling attenuates the progression of cachexia independent of changes in protein synthesis. Wild type and ApcMin/+ mice were given an IL-6 receptor antibody or PBS control at 16 weeks of age and sacrificed at 18 weeks. A) Experimental design showing administration schedule and time line of IL-6 receptor antibody or PBS treatment. B) Percentage body weight change from peak body weight to sacrifice weight. C) Polyp distribution presented in percentage of total tumors. D) Representative western blot of phosphorylated and total forms of Stat3 and total SOC3 protein expression. E) Gastrocnemius weight and F) muscle protein synthesis measured at sacrifice. G) IGF-1 gene expression in the gastrocnemius muscle. H) Upper: Representative western blots of phosphorylated and total forms of Akt, mTOR, p70S6K, and 4E-BP1. Lower: The ratio of phosphorylated to total form of the given protein normalized to PBS treated wild-type mice. Values are means ± SE. Significance was set at p<0.05. *Signifies difference within treatment. † Signifies difference within genotype. # Signifies main effect of genotype. & Signifies difference in polyps 1–2 mm. $ Signifies difference between polyps >2 mm.
Figure 5 Inhibition of IL-6 signaling attenuates the progression of cachexia independent of changes in protein synthesis. Wild type and ApcMin/+ mice were given an IL-6 receptor antibody or PBS control at 16 weeks of age and sacrificed at 18 weeks. A) Experimental design showing administration schedule and time line of IL-6 receptor antibody or PBS treatment. B) Percentage body weight change from peak body weight to sacrifice weight. C) Polyp distribution presented in percentage of total tumors. D) Representative western blot of phosphorylated and total forms of Stat3 and total SOC3 protein expression. E) Gastrocnemius weight and F) muscle protein synthesis measured at sacrifice. G) IGF-1 gene expression in the gastrocnemius muscle. H) Upper: Representative western blots of phosphorylated and total forms of Akt, mTOR, p70S6K, and 4E-BP1. Lower: The ratio of phosphorylated to total form of the given protein normalized to PBS treated wild-type mice. Values are means ± SE. Significance was set at p<0.05. *Signifies difference within treatment. † Signifies difference within genotype. # Signifies main effect of genotype. & Signifies difference in polyps 1–2 mm. $ Signifies difference between polyps >2 mm.CC BY · PubMed Central
Figure 6 Administration of IL-6 receptor antibody attenuates the increase of phosphorylation of AMPK and raptor. A). Upper: representative western blot of phosphorylated and total forms of AMPK. Lower: The ratio of phosphorylated and total AMPK expression normalized to wild-type PBS control. B). Upper: representative western blot of phosphorylated and total forms of raptor. Lower: The ratio of phosphorylated and total forms of raptor. Values are means ± SE. Significance was set at p<0.05. *Signifies difference within treatment. † Signifies difference within genotype.
Figure 6 Administration of IL-6 receptor antibody attenuates the increase of phosphorylation of AMPK and raptor. A). Upper: representative western blot of phosphorylated and total forms of AMPK. Lower: The ratio of phosphorylated and total AMPK expression normalized to wild-type PBS control. B). Upper: representative western blot of phosphorylated and total forms of raptor. Lower: The ratio of phosphorylated and total forms of raptor. Values are means ± SE. Significance was set at p<0.05. *Signifies difference within treatment. † Signifies difference within genotype.CC BY · PubMed Central
Figure 7 IL-6 inhibition by IL-6 receptor antibody attenuates protein degradation and ubiquitin proteasomal degradation. Wild type and ApcMin/+ mice were given an IL-6 receptor antibody or PBS control at 16 weeks of age and sacrificed at 18 weeks. A) Protein degradation determined by tyrosine release assay. White bars represent ATP dependent degradation; Black bars represent ATP independent degradation. B) Upper representative western blot of ubiquitinated proteins in the gastrocnemius muscle. Lower Quantification of ubiquitinated proteins normalized to wild-type PBS control mice. C) Gene expression of C7 and C2 proteasomal subunits. D) Upper: representative western blot of phosphorylated and total forms of Foxo3. Lower: The ratio of phosphorylated and total Foxo3. E) Gene expression of atrogin1 and MuRF1. F) Representative western blot of atrogin1 protein. Values are means ± SE. Significance was set at p<0.05. *Signifies difference from wild-type control. † Signifies difference within ApcMin/+ mice.
Figure 7 IL-6 inhibition by IL-6 receptor antibody attenuates protein degradation and ubiquitin proteasomal degradation. Wild type and ApcMin/+ mice were given an IL-6 receptor antibody or PBS control at 16 weeks of age and sacrificed at 18 weeks. A) Protein degradation determined by tyrosine release assay. White bars represent ATP dependent degradation; Black bars represent ATP independent degradation. B) Upper representative western blot of ubiquitinated proteins in the gastrocnemius muscle. Lower Quantification of ubiquitinated proteins normalized to wild-type PBS control mice. C) Gene expression of C7 and C2 proteasomal subunits. D) Upper: representative western blot of phosphorylated and total forms of Foxo3. Lower: The ratio of phosphorylated and total Foxo3. E) Gene expression of atrogin1 and MuRF1. F) Representative western blot of atrogin1 protein. Values are means ± SE. Significance was set at p<0.05. *Signifies difference from wild-type control. † Signifies difference within ApcMin/+ mice.CC BY · PubMed Central
Figure 8 The induction of autophagy is attenuated by IL-6 inhibition. A) Upper representative western blot of Beclin-1 protein. Lower Quantification of Beclin-1 protein normalized to wild-type PBS control mice. B) Upper representative western blot of Atg7 protein. Lower Quantification of Atg7 protein normalized to wild-type PBS control mice. C) Upper representative western blot of LC3β protein. Lower Quantification of LC3β protein normalized to wild-type PBS control mice. Values are means ± SE. Significance was set at p<0.05. *Signifies difference from wild type control. † Signifies difference within ApcMin/+ mice.
Figure 8 The induction of autophagy is attenuated by IL-6 inhibition. A) Upper representative western blot of Beclin-1 protein. Lower Quantification of Beclin-1 protein normalized to wild-type PBS control mice. B) Upper representative western blot of Atg7 protein. Lower Quantification of Atg7 protein normalized to wild-type PBS control mice. C) Upper representative western blot of LC3β protein. Lower Quantification of LC3β protein normalized to wild-type PBS control mice. Values are means ± SE. Significance was set at p<0.05. *Signifies difference from wild type control. † Signifies difference within ApcMin/+ mice.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. ML Asp, 2010, Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice., Int J Cancer, 126, 756, 10.1002/ijc.24784 · DOI
  2. RA Frost, 2007, Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass., J Appl Physiol, 103, 378, 10.1152/japplphysiol.00089.2007 · DOI · Paper page

Cited by

Sorted by citations

See all 260

Metadata

Authors
White, J. P., Baynes, J. W., Welle, S. L., Kostek, M. C., Matesic, L. E., Sato, S., & Carson, J. A.
Affiliations
  • University of South Carolina (US)
  • University of Rochester Medicine (US)
Corresponding author
Carson, James A.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2011-09-19
Volume
6
Issue
9
Pages
e24650
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0024650
PMC
PMC3176277
OpenAlex
W2151316758
Cited by
260
References
82
Citations by year
2026: 8 · 2025: 16 · 2024: 21 · 2023: 22 · 2022: 20 · 2021: 29 · 2020: 24 · 2019: 18 · 2018: 18 · 2017: 19 · 2016: 11 · 2015: 11 · 2014: 12 · 2013: 17 · 2012: 12
FWCI
5.59
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Scholar Commons (University of South Carolina) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • Chugai Pharmaceutical
  • National Cancer Institute (R01CA121249)
  • National Center for Research Resources (P20RR017698)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
Keywords
cancer cachexia, skeletal muscle protein turnover, muscle protein synthesis, muscle protein degradation, colorectal cancer, IL-6 signaling, AMPK, Raptor phosphorylation, muscle atrophy, weight loss, IL-6 receptor antibody
MeSH terms
Adenosine Triphosphate, Animals, Body Weight, Cachexia, Enzyme Activation, Inflammation, Insulin-Like Growth Factor I, Mice, Inbred C57BL, Mice, Mutant Strains, Muscle Proteins, Myofibrils, Neoplasms, Organ Size, Phosphorylation, Protein Biosynthesis, Signal Transduction, Interleukin-6, Disease Progression, Muscle, Skeletal, Adiposity, Mice, AMP-Activated Protein Kinases, TOR Serine-Threonine Kinases, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review